Fighting secondary triple-negative breast cancer in cerebellum: A powerful aid from a medicinal mushrooms blend

Biomed Pharmacother. 2023 Mar:159:114262. doi: 10.1016/j.biopha.2023.114262. Epub 2023 Jan 17.

Abstract

Breast cancer (BC) is the second most common cause of brain metastasis onset in patients, with the cerebellum accounting for the 33% of cases. In the current study, using a 4T1 triple-negative mouse BC model, we revealed that an orally administered medicinal mushrooms (MM) blend, rich in β-glucans, played a direct and specific anti-cancer action on cerebellar metastases, also bettering locomotor performances. The neuroprotective effect of the MM blend plays through (i) a direct and specific inhibition of cerebellar metastatization pattern typical of TNBC (with an induced reduction of about 50% of metastases density) and (ii) the regulation of apoptosis and proliferation-related genes, as suggested by expression changes of specific molecular markers, i.e. PCNA, p53, Bcl2, BAX, CASP9, CASP3, Hsp70 and AIF. Therefore, inhibiting the metastatization process, triggering a significant apoptosis increase, and lessening cell proliferation, this MM supplement, employed as adjuvant treatment in association with conventional therapy, could represent a promising approach, in the field of Integrative Oncology, for patients' management in both prevention and treatment of brain metastases from BC.

Keywords: Apoptosis; Cancer proliferation; Cerebellum; Integrative medicine; Locomotor activity; Medicinal mushrooms; Metastases; TNBC.

MeSH terms

  • Agaricales*
  • Animals
  • Apoptosis
  • Brain Neoplasms* / secondary
  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • Mice
  • Triple Negative Breast Neoplasms* / metabolism